tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2019-9-2-74-80tumors-638Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL NOTESСлучай использования ингибитора контрольных точек у больной раком шейки матки в реальной клинической практикеA case report of cervical cancer treated with a checkpoint inhibitor in a real-world clinical settingОрловаР. В.OrlovaR. V.

Рашида В. Орлова - доктор медицинских наук, профессор, заведующая кафедрой онкологии СПБГУ

orlova_rashida@mail.ruТюкавинаН. В.TyukavinaN. V.

Нина В. Тюкавина - врач-онколог, заведующая онкологическим отделением СПб ГБУЗ ГБ № 40

Nina V. Tyukavina - Oncologist, Head of the Department of Oncology.

St. Petersburg

tyukavina@yandex.ruГлузманМ. И.GluzmanM. I.

Марк И. Глузман - ассистент кафедры факультетской хирургии СПБГУ, врач-онколог СПб ГБУЗ ГБ № 40

lok2008@list.ruПротасоваА. Э.ProtasovaA. E.

Анна Э. Протасова - доктор медицинских наук, профессор кафедры онкологии медицинского факультета СПБГУ, руководитель Центра онкологии ООО «АВА-ПЕТЕР»

Anna E. Protasova - MD, PhD, DSc, Professor Department of Oncology Faculty MSPSU, Head of the Department of Oncology Clinic of Reproductive Medicine AVA-PETER LLC

protasova1966@yandex.ruРаскинГ. А.RaskinG. A.

Григорий А. Раскин - доктор медицинских наук, профессор кафедры онкологии медицинского факультета СПБГУ, руководитель отдела патологической анатомии ФГБУ «РНЦРХТ им.академика А.М. Гранова

Grigoriy A. Raskin - MD, PhD, DSc, Professor Department of Oncology Faculty MSPSU, Head of the Division of Pathology A.M. Granov RRCRST

rasking@list.ruХаликовА. Д.KhalikovА. D.

Азиз Д. Халиков - кандидат медицинских наук, заведующий отделением МРТ и КТ клиники.

Санкт-Петербург

Aziz D. Khalikov - MD, PhD, Head of the Department of MRI and CT.

St. Petersburg

ФГБОУ ВО Санкт-Петербургский государственный университетРоссияSaint Petersburg State UniversityRussian FederationСПб ГБУЗ Городская больница № 40 Курортного районаРоссияMunicipal Hospital No. 40 of Kurortnyi DistrictRussian FederationФГБОУ ВО Санкт-Петербургский государственный университет; СПб ГБУЗ Городская больница № 40 Курортного районаРоссияSaint Petersburg State University; Municipal Hospital No. 40 of Kurortnyi DistrictRussian FederationФГБОУ ВО Санкт-Петербургский государственный университет; Клиника репродуктивной медицины ООО «АВА-ПЕТЕР»РоссияSaint Petersburg State University; Reproductive Medicine Clinic AVA-PETER LLCRussian FederationФГБОУ ВО Санкт-Петербургский государственный университет; ФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава РоссииРоссияSaint Petersburg State University; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. GranovaRussian FederationКлиника репродуктивной медицины ООО «АВА-ПЕТЕР»РоссияReproductive Medicine Clinic AVA-PETER LLCRussian Federation201927062019927480Copyright © Орлова Р.В., Тюкавина Н.В., Глузман М.И., Протасова А.Э., Раскин Г.А., Халиков А.Д., 20192019Орлова Р.В., Тюкавина Н.В., Глузман М.И., Протасова А.Э., Раскин Г.А., Халиков А.Д.Orlova R.V., Tyukavina N.V., Gluzman M.I., Protasova A.E., Raskin G.A., Khalikov А.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/638

Стандартом лечения IVB стадии рака шейки матки является паллиативная лекарственная терапия в комплексе с циторедуктивными операциями при наличии резектабельных очагов. Основа противоопухолевой терапии — двухкомпонентные режимы с включением препаратов платины и таксанового ряда. Вирус-ассоциированный этиопатогенетический механизм развития рака шейки матки является предиктором высокой эффективности иммунотерапии, в связи с чем в 2018 году FDA одобрила применение анти-PD1 препарата в лечении больных данной группы. В статье приведены литературные сведения о методах лечения распространенного рака шейки матки, и представлен клинический случай торпидного течения заболевания, в лечении которого применялись все существующие на сегодняшний день терапевтические опции, в том числе ингибиторы контрольных точек.

The treatment standard for stage IVB cervical cancer is palliative drug therapy combined with cytoreductive surgery used in the presence of resectable lesions. Anticancer therapy is based on two-component regimens that include platinum agents and taxanes. The virus-associated aetiology and pathogenesis of cervical cancer is a predictor of high efficacy of immunotherapy, which made the FDA approve an anti-PD1 agent for use in the treatment of these patients in 2018. The paper presents literature data on the treatment methods for advanced cervical cancer and a case report of indolent disease that was treated with all currently available therapeutic options, including checkpoint inhibitors.

рак шейки маткииммунотерапияингибиторы иммунных контрольных точекниволумабcervical cancerimmunotherapyimmune checkpoint inhibitorsnivolumabReferencesBray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / F. Bray, J. Ferlay, I. Soerjomataram et al. // CA: A Cancer Journal for Clincians. — 2018. — Vol. 68. — № 6. — p. 394-424Bray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / F. Bray, J. Ferlay, I. Soerjomataram et al. // CA: A Cancer Journal for Clincians. — 2018. — Vol. 68. — № 6. — p. 394-424Parikh S. Meta-analysis of social inequality and the risk of cervical cancer/ S. Parikh, P. Brennan, P. Boffetta // Int. J. Cancer. — 2003. — Vol. 105 (5). — p. 687-691.Parikh S. Meta-analysis of social inequality and the risk of cervical cancer/ S. Parikh, P. Brennan, P. Boffetta // Int. J. Cancer. — 2003. — Vol. 105 (5). — p. 687-691.Siegel R. Cancer statistics / R. Siegel, J. Ma, Z. Zou. / CA Cancer J Clin. — 2014. — Vol. 64 (1). — p. 9-29.Siegel R. Cancer statistics / R. Siegel, J. Ma, Z. Zou. / CA Cancer J Clin. — 2014. — Vol. 64 (1). — p. 9-29.Minion L.E. Cervical cancer — State of the science: From angiogenesis blockade to checkpoint inhibition/L.E. Minion, K.S. Tewari // Gynecol Oncol. — 2018. — Vol. 148 (3). — p. 609-621.Minion L.E. Cervical cancer — State of the science: From angiogenesis blockade to checkpoint inhibition/L.E. Minion, K.S. Tewari // Gynecol Oncol. — 2018. — Vol. 148 (3). — p. 609-621.Ijaz T. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma/T. Ijaz, P.J. Eifel, T. Burke // Gynecol Oncol. — 1998. — Vol. 70 (2). — p. 241-246.Ijaz T. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma/T. Ijaz, P.J. Eifel, T. Burke // Gynecol Oncol. — 1998. — Vol. 70 (2). — p. 241-246.Thomas G.M. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery/ G.M. Thomas, A.J. Dembo, B. Black et al. // Gynecol Oncol. — 1987. — Vol. 27 (3). — p. 254-263.Thomas G.M. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery/ G.M. Thomas, A.J. Dembo, B. Black et al. // Gynecol Oncol. — 1987. — Vol. 27 (3). — p. 254-263.Eskander R.N. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer / R.N. Eskander, K.S. Tewari // Curr Opin Obstet Gynecol. — 2014. — Vol. 26 (4). — p. 314-321.Eskander R.N. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer / R.N. Eskander, K.S. Tewari // Curr Opin Obstet Gynecol. — 2014. — Vol. 26 (4). — p. 314-321.Monk B.J. Evidence-based therapy for recurrent cervical cancer / B.J. Monk, K.S. Tewari // J Clin Oncol. — 2014. — Vol. 32 (25). — p. 2687-2690.Monk B.J. Evidence-based therapy for recurrent cervical cancer / B.J. Monk, K.S. Tewari // J Clin Oncol. — 2014. — Vol. 32 (25). — p. 2687-2690.Monk B.J. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study/B.J. Monk, M.W. Sill, D.S. McMeekin et al. // J. Clin. Oncol. — 2009. — Vol. 27 (28). — p. 4649-4655.Monk B.J. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study/B.J. Monk, M.W. Sill, D.S. McMeekin et al. // J. Clin. Oncol. — 2009. — Vol. 27 (28). — p. 4649-4655.Tewari K.S. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma/K.S. Tewari, B.J. Monk // Clin. Adv. Hematol. Oncol. — 2010. — Vol. 8 (2). — p. 108-115.Tewari K.S. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma/K.S. Tewari, B.J. Monk // Clin. Adv. Hematol. Oncol. — 2010. — Vol. 8 (2). — p. 108-115.Tewari K.S. Improved survival with bevacizumab in advanced cervical cancer / K.S. Tewari, M.W. Sill, H.J. Long III et al. // N Engl J Med. — 2014. — Vol. 370 (8). — p. 734-743.Tewari K.S. Improved survival with bevacizumab in advanced cervical cancer / K.S. Tewari, M.W. Sill, H.J. Long III et al. // N Engl J Med. — 2014. — Vol. 370 (8). — p. 734-743.Burd E.M. Human Papillomavirus and Cervical Cancer/E.M. Burd // Clin Microbiol Rev. — 2003. — Vol. 16 (1). — p. 1-17.Burd E.M. Human Papillomavirus and Cervical Cancer/E.M. Burd // Clin Microbiol Rev. — 2003. — Vol. 16 (1). — p. 1-17.Crosbie E.J. Human papillomavirus and cervical cancer / E.J. Crosbie, M.H. Einstein, S. Franceschi et al. // Lancet. — 2013. — Vol. 382 (9895). — p. 889-899.Crosbie E.J. Human papillomavirus and cervical cancer / E.J. Crosbie, M.H. Einstein, S. Franceschi et al. // Lancet. — 2013. — Vol. 382 (9895). — p. 889-899.Yang W. Increased expression of programmed death (PD) — 1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia/W. Yang, Y. Song, Y.L. Lu et al. // Immunol. — 2013. — Vol. 139 (4). — p. 513-522.Yang W. Increased expression of programmed death (PD) — 1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia/W. Yang, Y. Song, Y.L. Lu et al. // Immunol. — 2013. — Vol. 139 (4). — p. 513-522.Howitt BE. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva / B.E. Howitt, H.H. Sun, M.G. Roemer et al. // JAMA Oncol. — 2016. — Vol. 2 (4). — p. 518-522.Howitt BE. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva / B.E. Howitt, H.H. Sun, M.G. Roemer et al. // JAMA Oncol. — 2016. — Vol. 2 (4). — p. 518-522.Roszik J. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy/J. Roszik, K.L. Ring, K.M. Wani et al. // Front Immunol. — 2018. — Vol. 9 (2102). Availeble online: doi: 10.3389/fimmu.2018.02102.Roszik J. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy/J. Roszik, K.L. Ring, K.M. Wani et al. // Front Immunol. — 2018. — Vol. 9 (2102). Availeble online: doi: 10.3389/fimmu.2018.02102.Hollebecque A. An Open-label, Multicohort, Phase I/II Study of Nivolumab in Patients With Virus-associated Tumors (CheckMate 358): Efficacy and Safety in Recurrent or Metastatic (R/M) Cervical, Vaginal, and Vulvar Cancers/ A. Hollebecque, T. Meyer, K.N. Moore et al. // J. Clin. Oncol. — 2017. — Vol. 35 (15 suppl) — p. 5504.Hollebecque A. An Open-label, Multicohort, Phase I/II Study of Nivolumab in Patients With Virus-associated Tumors (CheckMate 358): Efficacy and Safety in Recurrent or Metastatic (R/M) Cervical, Vaginal, and Vulvar Cancers/ A. Hollebecque, T. Meyer, K.N. Moore et al. // J. Clin. Oncol. — 2017. — Vol. 35 (15 suppl) — p. 5504.U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT02257528, Accessed date: 4 November 2017U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT02257528, Accessed date: 4 November 2017Frenel J.S. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1positive cervical cancer: results from the phase Ib KEYNOTE-028 trial / J.S. Frenel, C. Le Tourneau, B. O»Neil et al. // J. Clin. Oncol. -2017. — Vol. 35 (36). — p. 4035-4041.Frenel J.S. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1positive cervical cancer: results from the phase Ib KEYNOTE-028 trial / J.S. Frenel, C. Le Tourneau, B. O»Neil et al. // J. Clin. Oncol. -2017. — Vol. 35 (36). — p. 4035-4041.Chung H.C. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study/H.C. Chung, J.H. M. Schellens, J.P. Delord et al. // Journal of Clinical Oncology. — 2018. — Vol. 36 (15_suppl). -p. 5522-5522.Chung H.C. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study/H.C. Chung, J.H. M. Schellens, J.P. Delord et al. // Journal of Clinical Oncology. — 2018. — Vol. 36 (15_suppl). -p. 5522-5522.U.S. Food and Drug Administration: FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. Available at www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htmU.S. Food and Drug Administration: FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. Available at www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm

The authors declare that there are no conflicts of interest present.